Our Raw Material Support Includes
Comprehensive support for selecting high-quality pharmaceutical-grade raw materials, including vendor qualification, specification review, excipient compatibility studies, impurity risk assessment, pharmacopeial compliance verification, and regulatory documentation, to ensure stable formulations, smooth scale-up, GMP compliance, and reliable commercial manufacturing readiness.
Global Regulatory Market Assessment
- Comprehensive regulatory evaluation: Assessment of raw material acceptability across USFDA, EFSA, FSSAI, CDSCO, GCC, ASEAN, and EU frameworks, ensuring unrestricted commercial applicability.
- Restricted substance screening: Scientific evaluation of excipients, additives, solvents, residual impurities, heavy metals, allergens, GMO status, BSE/TSE risk against regional restrictions.
- Import eligibility verification: Confirmation of country-specific compliance, including permissible usage limits, certification requirements, and technical declarations for international market entry.
- Documentation readiness support: Preparation of regulatory dossiers, technical declarations, import permits, ensuring smooth cross-border material sourcing and commercial distribution.
Pharmaceutical-Grade Lecithin Excellence
- Highly purified lecithin advantage: Exclusive use of saturated and refined lipids through multi-step purification, eliminating unstable fatty acids causing colour/odour degradation.
- Bio-identical phospholipid composition: Enriched with Phosphatidylcholine (PC) and Phosphatidylethanolamine (PE), ensuring skin affinity, vesicle stability, and crystal-clear transparency.
- Colour and odour stability: Purified lipids are virtually immune to light- and air-induced sensory degradation, maintaining freshness from first use to last.
- Vesicle integrity assurance: Stable lipid chains form robust, rigid bilayer tructures essential for protecting sensitive actives from environmental egradation.
Country-Wise Pharmacopoeia Compliance
- Pharmacopoeial monograph qualification: Scientific evaluation and qualification according to USP, BP, EP, IP, JP, and FCC country-specific monographs, ensuring regulatory acceptance.
- Country-specific specification compliance: Technical verification of assay limits, impurity profiles, residual solvents, heavy metals, microbial limits per destination-country frameworks.
- Regulatory documentation preparation: Pharmacopoeia-compliant specifications, Certificates of Analysis (COA), TDS, MSDS, declarations for seamless international registration and import approval.
- Market authorisation support: Complete technical dossiers supporting commercial distribution across multiple jurisdictions with jurisdiction-specific compliance documentation.
Pharmaceutical-Grade Actives Library
- Multi-molecular hyaluronic acid: Sourced for deep hydration and clear viscosity, maintaining transparency while delivering multi-weight molecular penetration profiles.
- Stabilised vitamin C (ascorbic acid): Selected for superior stability, preventing crystallisation within the system, ensuring long-term potency and sensory integrity.
- Targeted acids (glycolic & salicylic): Sourced at purity levels preventing pH-dri, ft which causes liposomal rupt,ure ensuring formulation stability throughout shelf life.
- Specialised therapeutic actives: High-potency actives like diclofenac and methyl salicylate free from heavy metals and irritants for safe long-term topical use.
Elemental Impurity & Heavy Metal Assessment
- Comprehensive elemental evaluation: Assessment of elemental impurities, heavy metals, residual catalysts, trace contaminants per ICH guidelines and pharmacopeial standards.
- Regulatory safety compliance: Verification against global regulatory safety requirements, ensuring acceptable limits across pharmaceutical, nutraceutical, and cosmeceutical applications.
- Risk-based material qualification: ICH Q3D-aligned evaluation ensuring elemental impurity control throughout the supply chain from raw material through finished product.
- Batch-specific documentation: Certificate of Analysis (COA) confirmation for every material batch, ensuring traceability and audit readiness for regulatory inspection.
Residual Solvent & Contaminant Compliance
- Residual solvent assessment: Scientific evaluation per ICH Q3C guidelines, ensuring acceptable limits for Class 1, 2, and 3 solvents in pharmaceutical formulations.
- Microbiological contaminant screening: Testing for total aerobic count, yeast, mould, and pathogens, ensuring materials meet pharmacopeial microbial limits for product safety.
- Aflatoxin and dioxin evaluation: Risk assessment for mycotoxins and environmental contaminants, particularly critical for botanical extracts and natural-source materials.
- Process-related impurity control: Identification and quantification of synthesis by-products, degradation products, and reaction intermediates, ensuring material purity and formulation compatibility
Toxicological & Allergen Safety Evaluation
- Toxicological profile review: Detailed assessment of acute toxicity, chronic toxicity, genotoxicity, and reproductive toxicity supporting risk-free formulation development and regulatory submission.
- Allergen declaration verification: Confirmation of allergen presence (gluten, soy, dairy, nuts) supporting clean-label claims and consumer safety requirements.
- GMO/BSE/TSE status confirmation: Documentation of genetic modification status, bovine/transmissible spongiform encephalopathy risk for materials of animal or plant origin.
- Excipient safety validation: Review of historical safety data, published literature, and regulatory monographs, ensuring excipient acceptability for intended application and target population.
Synergy & Bio-Compatibility
- Bio-identical lipid selection: Utilisation of lipids matching skin’s cellular membranes enabling “Local-First” delivery without surface irritation from synthetic formulations.
- Essential fatty acid donors: High-purity EFA donors and intrinsic lipid-phase stabilisers create a lipid environment that skin absorbs readily, enhancing dermal penetration.
- Thermal resilience engineering: Materials selected for withstanding high-energy manufacturing environments where temperature spikes could cause standard lipids to break down.
- Superior skin-feel optimisation: Pharmaceutical-grade selection delivers a sophisticated, non-tacky texture that mimics natural phospholipids for an enhanced consumer sensory experience.
Pharmaceutical-Grade Material Selection
- Pharmacopoeia-compliant API sourcing: Strategic procurement of USP, BP, EP, IP-grade active pharmaceutical ingredients aligned with global GMP regulatory standards.
- High-purity phospholipid qualification: Selection of pharmaceutical-grade phosphatidylcholine, phosphatidylethanolamine, sphingomyelin for superior vesicle formation and stability.
- Functional excipient engineering: Coating polymers, release-modifying agents, and enteric materials selected for high-performance pharmaceutical formulations requiring controlled drug delivery.
- Regulatory documentation completeness: Full technical dossiers including drug master files (DMF), certificates of suitability (CEP), and regulatory support files for authority submissions.
Segment-Specific Raw Material Approach
- FSSAI-compliant material selection: Qualification of nutraceutical actives, bioavailable mineral salts, vitamins meeting Food Safety and Standards Authority of India requirements.
- Botanical extract standardisation: Selection of standardised herbal extracts with defined marker compounds ensuring batch-to-batch potency consistency and formulation reproducibility.
- Amino acid and peptide sourcing: High-purity fermentation-derived or synthetic amino acids for sports nutrition, anti-ageing, and functional food applications.
- Liposomal carrieroptimisation: Specialised phospholipids, emulsifiers, stabilisers designed for superior nutrient absorption, stability, and consumer-ready dosage form development.
Application-Based Excipient Engineering
- Dosage form functionality: Technical identification of binders, diluents, disintegrants, lubricants, glidants based on tablet, capsule, powder, liquid formulation requirements.
- Process compatibility assessment: Selection of excipients compatible with wet granulation, direct compression, spray drying, homogenization, and sonication manufacturing processes.
- Stabiliser and preservative systems: Antioxidants, chelating agents, and antimicrobial preservatives optimised for formulation pH, water activity, and packaging compatibility, ensuring shelf-life stability.
- Release-modifying agent selection: Polymers, waxes, lipids engineered for immediate, sustained, delayed, or targeted release profiles meeting therapeutic or nutritional delivery objectives.
Transparency as Quality Metric
- Refractive index verification: Every material vetted for optical properties ensures formulations remain crystal-clear, without waxes or low-purity surfactants that can cause cloudiness.
- Particle-size potential assessment: Material evaluation ensuring compatibility with nano-scale processing, maintaining precise vesicle dimensions, preventing light scattering and turbidity.
- Ultra-pure formulation strategy: “Lean” formulas carrying high-potency actives deep into dermis enabled by materials free from heavy fillers or unnecessary excipients.
- Visual quality confirmation: Transparency that proves pharmaceutical-grade purity, allowing consumers to verify product quality visually and the manufacturer’s commitment to excellence.
Market-Specific Compliance Includes
Raw material qualification based on FSSAI, CDSCO, USFDA, EU, GCC, ASEAN frameworks, ensuring seamless development and approval.
Complete documentation packages supporting international product registration, import licensing, and commercial distribution across regulated markets.
Verification of permissible concentrations, restricted substances, and labelling requirements per destination country, ensuring full regulatory compliance.
All materials linked to recognised pharmacopeial monographs supporting regulatory submissions, audits, and quality system documentation requirements.
Raw Material Troubleshooting
Batch-to-batch variation, specification drift, impurity spikes resolved through vendor qualification
Pharmacopeial non-conformance, restricted substances, import restrictions addressed through market screening
Excipient interactions, pH instability, precipitation issues corrected through compatibility studies
Heavy metals, residual solvents, microbial contamination controlled through comprehensive safety review
Commercial quantity availability, multiple vendor qualification, supply chain continuity established
Raw Material Qualification & Regulatory Readiness
Evaluation Of Pharmaceutical-grade Apis, Phospholipids, Excipients Based On Purity, Pharmacopeial Compliance, Regulatory Acceptability Across Target Markets.
Comprehensive Supplier Assessment Including Gmp Certification, Analytical Capabilities, Regulatory Documentation, Quality System Inspection Supporting Approved Vendor Status.
Physicochemical Compatibility Studies, Accelerated Stability Assessment, Excipient Interaction Evaluation Ensuring Formulation Integrity And Long-term Product Performance.
Review of material specifications, certificate of analysis, test methods, and acceptance criteria, ensuring alignment with pharmacopeial standards and regulatory requirements.
Why Partner with Lipoedge for Raw Material Support
High-purity APIs, phospholipids, excipients with full pharmacopeial compliance (USP, BP, EP, IP, JP, FCC), ensuring superior formulation integrity.
Comprehensive screening across FSSAI, CDSCO, USFDA, EFSA, GCC, ASEAN, and EU frameworks, ensuring unrestricted material acceptance and market access.
Scientific evaluation of elemental impurities, heavy metals, residual solvents, and microbial contamination, ensuring toxicological safety and regulatory acceptance.
Precision selection of binders, emulsifiers, surfactants, stabilisers based on physicochemical compatibility and dosage form functionality, improving product stability.
Preparation of specifications, COA, TDS, MSDS, declarations, submission-ready dossiers, ensuring audit readiness and regulatory transparency.
Ready to Elevate Your
Formulation Testing?
Partner with LipoEdge's expert scientific team for end-to-end in vitro analytical support — from study design to regulatory submission.
Frequently Asked Questions
In vitro chemical testing generates release, stability, and bioaccessibility data, enabling informed formulation decisions across nutraceutical, pharmaceutical, and cosmeceutical product development pipelines. This reduces development uncertainty, supports faster optimisation of dosage forms, and strengthens technical confidence before scale-up, validation, and regulatory submission stages.
The INFOGEST model simulates human digestion conditions across salivary, gastric, and intestinal phases, enabling realistic evaluation of liposomal stability and release behaviour. It helps predict oral bioavailability, validate formulation performance under physiological conditions, and support scientifically substantiated claims for product positioning and regulatory documentation.
Dialysis and simulated digestion studies quantify controlled release behaviour, enabling clear differentiation between liposomal systems and conventional formulations in performance-driven markets. This supports claims of sustained delivery, improved absorption, and enhanced functionality, strengthening product positioning across competitive nutraceutical and pharmaceutical segments globally.
LipoEdge provides integrated in vitro testing using validated digestion models, diffusion systems, and antioxidant assays to ensure reliable and reproducible analytical outcomes. It enables clients to generate regulatory-aligned data, optimise formulations effectively, and accelerate product development timelines with strong technical and commercial confidence.
LipoEdge combines formulation understanding with analytical expertise, enabling customised study designs tailored to liposomal, nanosomal, and encapsulated delivery systems across applications. This ensures deeper insight into product behaviour, improved interpretation of results, and stronger alignment between laboratory findings and real-world product performance expectations.